Cellectar Biosciences partners with AON

Cellectar Biosciences announced a partnership to advance the treatment of Waldenstrom’s macroglobulinemia, or WM, in the community setting with American Oncology Network, or AON, a leading oncology platform with an innovative model of physician-led, community-based oncology management, and its data arm subsidiary Meaningful Insights-BioTech Analytics, or MiBA, a healthcare AI technology company on a mission to close the feedback loop between physicians, patients, and industry partners. Positive topline data from the pivotal Clover WaM study for iopofosine I 131 was reported on January 8, achieving the primary endpoint with a 61% major response rate, or MRR, and exceeding the protocol statistical hurdle of 20%. This was the largest study to date in relapsed or refractory WM patients post-BTKi therapy and represents the most refractory population ever tested in clinical studies based upon a review of published literature. Iopofosine I 131 was well tolerated and its toxicity profile was consistent with the Company’s previously reported safety data. AON is one of the fastest growing networks of community oncology practices with 85 sites of care across the U.S. focused on delivering high-quality cancer care.